PAVmed (NASDAQ:PAVM – Get Free Report) and Thermo Fisher Scientific (NYSE:TMO – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.
Profitability
This table compares PAVmed and Thermo Fisher Scientific’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PAVmed | 10,672.42% | -754.98% | -19.87% |
| Thermo Fisher Scientific | 15.05% | 16.92% | 8.36% |
Earnings and Valuation
This table compares PAVmed and Thermo Fisher Scientific”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PAVmed | $29,000.00 | 356.28 | $39.79 million | ($17.12) | -0.61 |
| Thermo Fisher Scientific | $44.56 billion | 4.24 | $6.70 billion | $17.74 | 28.66 |
Thermo Fisher Scientific has higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
PAVmed has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and price targets for PAVmed and Thermo Fisher Scientific, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PAVmed | 1 | 1 | 1 | 0 | 2.00 |
| Thermo Fisher Scientific | 0 | 2 | 18 | 1 | 2.95 |
PAVmed currently has a consensus target price of $510.00, indicating a potential upside of 4,757.14%. Thermo Fisher Scientific has a consensus target price of $633.68, indicating a potential upside of 24.62%. Given PAVmed’s higher possible upside, research analysts plainly believe PAVmed is more favorable than Thermo Fisher Scientific.
Insider & Institutional Ownership
19.9% of PAVmed shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 5.8% of PAVmed shares are owned by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Thermo Fisher Scientific beats PAVmed on 11 of the 15 factors compared between the two stocks.
About PAVmed
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.
